Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B10 | O60218 | 2/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23702414 | 0.93 | AKR1B10 (0.54) | AKR1B10AKR1B1CA12CA1CA2 | |
| SCHEMBL23702413 | 0.93 | AKR1B10 (0.54) | AKR1B10AKR1B1CA12CA1CA2 | |
| SCHEMBL15869772 | 0.91 | AKR1B10 (0.53) | AKR1B10AKR1B1CA12CA1CA2 | |
| SCHEMBL19900155 | 0.91 | AKR1B10 (0.53) | AKR1B10AKR1B1CA12CA1CA2 | |
| SCHEMBL5941427 | 0.90 | AKR1B10 (0.51) | AKR1B10AKR1B1CA12CA1CA2 | |
| SCHEMBL5941424 | 0.90 | AKR1B10 (0.51) | AKR1B10AKR1B1CA12CA1CA2 | |
| Isopropyl Cinnamate SCHEMBL133104 | 0.89 | AKR1B10 (0.72) | AKR1B10AKR1B1CA12CA1CA2 | |
| Isopropyl Cinnamate SCHEMBL133105 | 0.89 | AKR1B10 (0.72) | AKR1B10AKR1B1CA12CA1CA2 | |
| Isopropyl Cinnamate SCHEMBL11996898 | 0.89 | AKR1B10 (0.72) | AKR1B10AKR1B1CA12CA1CA2 | |
| SCHEMBL8854386 | 0.87 | AKR1B10 (0.56) | AKR1B10AKR1B1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952191-B2 | Ester resin compositions | XEROX CORPORATION (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952191-B2 | Ester resin compositions | XEROX CORPORATION (US) | 2015-02-10 | — | — | US | disclosed |
| US-8936359-B2 | Ink compositions incorporating ester resins | XEROX CORPORATION (US) | 2015-01-20 | — | — | US | disclosed |
| US-8936359-B2 | Ink compositions incorporating ester resins | XEROX CORPORATION (US) | 2015-01-20 | — | — | US | disclosed |
| US-8906150-B2 | Phase change inks containing crystalline trans-cinnamic diesters and polyterpene resins | XEROX CORPORATION (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906150-B2 | Phase change inks containing crystalline trans-cinnamic diesters and polyterpene resins | XEROX CORPORATION (US) | 2014-12-09 | — | — | US | disclosed |
| US-8778069-B2 | Phase change inks containing oligomeric rosin esters | XEROX CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778069-B2 | Phase change inks containing oligomeric rosin esters | XEROX CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140139591-A1 | INK COMPOSITIONS INCORPORATING ESTER RESINS | XEROX CORPORATION (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140137767-A1 | Phase Change Inks Containing Oligomeric Rosin Esters | XEROX CORPORATION (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140137767-A1 | Phase Change Inks Containing Oligomeric Rosin Esters | XEROX CORPORATION (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140139591-A1 | INK COMPOSITIONS INCORPORATING ESTER RESINS | XEROX CORPORATION (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142335-A1 | ESTER RESIN COMPOSITIONS | XEROX CORPORATION (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142335-A1 | ESTER RESIN COMPOSITIONS | XEROX CORPORATION (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130131226-A1 | Phase Change Inks Containing Crystalline Trans-Cinnamic Diesters and Polyterpene Resins | XEROX CORPORATION (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131226-A1 | Phase Change Inks Containing Crystalline Trans-Cinnamic Diesters and Polyterpene Resins | XEROX CORPORATION (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142335-A1 | ESTER RESIN COMPOSITIONS | ELL, ELOB, ELOC | AKR1B10 1565/4885AKR1B1 2282/4885CA12 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.